Risk Factors for Disease Progression and Treatment Goals in Polycythemia Vera

被引：0

作者：

Waksal, Julian A. ^{[1
]}

Wagner, Nicole E. ^{[2
]}

Mascarenhas, John O. ^{[1
,3
]}

机构：

[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[2] Icahn Sch Med, Dept Med, New York, NY USA

[3] T Canc Inst, Tisch Canc Inst, Div Hematol Oncol, Med, One Gustave L Levy Pl,Box 1079, New York, NY 10029 USA

来源：

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2024年 / 22卷 / 01期

关键词：

Debated practices; disease progression; myeloprolif- erative neoplasm; polycythemia vera; INTERNATIONAL-WORKING-GROUP; DEFINED ESSENTIAL THROMBOCYTHEMIA; REVISED RESPONSE CRITERIA; MYELOFIBROSIS RESEARCH; CARDIOVASCULAR EVENTS; CHRONIC INFLAMMATION; MYELOID METAPLASIA; IWG-MRT; LEUKOCYTOSIS; HYDROXYUREA;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Polycythemia vera is a Philadelphia chromosome-negative myeloproliferative neoplasm characterized by the clonal proliferation of hematopoietic cells, leading to the overproduction of erythrocytes and the elaboration of inflammatory cytokines. Management is aimed at reducing the risk of thromboembolic events, alleviating the symp-tom burden, decreasing splenomegaly, and potentially mitigating the risk of disease progression. Existing treatment options include thera-peutic phlebotomy and cytoreductive agents including hydroxyurea, pegylated recombinant interferon alpha 2a, ropegylated recombinant interferon alpha 2b, and ruxolitinib. We review risk factors for both thrombotic events and disease progression in patients with polycy-themia vera. We discuss existing and novel therapeutic approaches to mitigate the risk of disease-related complications and progression.

引用

页码：31 / 42

页数：12

共 92 条

[1] Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival [J].

Abu-Zeinah, Ghaith ;

Krichevsky, Spencer ;

Cruz, Tatiana ;

Hoberman, Gabriela ;

Jaber, Diana ;

Savage, Niamh ;

Sosner, Claudia ;

Ritchie, Ellen K. ;

Scandura, Joseph M. ;

Silver, Richard T. .

LEUKEMIA, 2021, 35 (09) :2592-2601

[2] Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study [J].

Accurso, Vincenzo ;

Santoro, Marco ;

Raso, Simona ;

Contrino, Angelo Davide ;

Casimiro, Paolo ;

Di Piazza, Florinda ;

Perez, Alessandro ;

Russo, Antonio ;

Siragusa, Sergio .

HEMATOLOGY REPORTS, 2019, 11 (04) :95-97

[3] Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera [J].

Alvarez-Larran, Alberto ;

Pereira, Arturo ;

Cervantes, Francisco ;

Arellano-Rodrigo, Eduardo ;

Hernandez-Boluda, Juan-Carlos ;

Ferrer-Marin, Francisca ;

Angona, Anna ;

Gomez, Montse ;

Muina, Begona ;

Guillen, Helga ;

Teruel, Anabel ;

Bellosillo, Beatriz ;

Burgaleta, Carmen ;

Vicente, Vicente ;

Besses, Carles .

BLOOD, 2012, 119 (06) :1363-1369

[4] Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients [J].

Alvarez-Larran, Alberto ;

Bellosillo, Beatriz ;

Martinez-Aviles, Luz ;

Saumell, Silvia ;

Salar, Antonio ;

Abella, Eugenia ;

Gimeno, Eva ;

Serrano, Sergi ;

Florensa, Lourdes ;

Sanchez, Blanca ;

Pedro, Carmen ;

Besses, Carles .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (05) :504-509

[5] ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients [J].

Andreasson, Bjorn ;

Pettersson, Helna ;

Wasslavik, Carina ;

Johansson, Peter ;

Palmqvist, Lars ;

Asp, Julia .

BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (05) :913-919

[6]

[Anonymous], FDA Approves Treatment for Ebola Virus | FDA

[7]

[Anonymous], 2021, Hydroxyurea [package insert]

[8] International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert P. ;

Borowitz, Michael J. ;

Calvo, Katherine R. ;

Kvasnicka, Hans-Michael ;

Wang, Sa A. ;

Bagg, Adam ;

Barbui, Tiziano ;

Branford, Susan ;

Bueso-Ramos, Carlos E. ;

Cortes, Jorge E. ;

Dal Cin, Paola ;

DiNardo, Courtney D. ;

Dombret, Herve ;

Duncavage, Eric J. ;

Ebert, Benjamin L. ;

Estey, Elihu H. ;

Facchetti, Fabio ;

Foucar, Kathryn ;

Gangat, Naseema ;

Gianelli, Umberto ;

Godley, Lucy A. ;

Gokbuget, Nicola ;

Gotlib, Jason ;

Hellstrom-Lindberg, Eva ;

Hobbs, Gabriela S. ;

Hoffman, Ronald ;

Jabbour, Elias J. ;

Kiladjian, Jean-Jacques ;

Larson, Richard A. ;

Le Beau, Michelle M. ;

Loh, Mignon L. -C. ;

Lowenberg, Bob ;

Macintyre, Elizabeth ;

Malcovati, Luca ;

Mullighan, Charles G. ;

Niemeyer, Charlotte ;

Odenike, Olatoyosi M. ;

Ogawa, Seishi ;

Orfao, Alberto ;

Papaemmanuil, Elli ;

Passamonti, Francesco ;

Porkka, Kimmo ;

Pui, Ching-Hon ;

Radich, Jerald P. ;

Reiter, Andreas ;

Rozman, Maria ;

Rudelius, Martina ;

Savona, Michael R. .

BLOOD, 2022, 140 (11) :1200-1228

[9] Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications [J].

Arranz, Lorena ;

Arriero, Maria del Mar ;

Villatoro, Alicia .

BLOOD REVIEWS, 2017, 31 (05) :306-317

[10] Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms [J].

Arranz, Lorena ;

Sanchez-Aguilera, Abel ;

Martin-Perez, Daniel ;

Isern, Joan ;

Langa, Xavier ;

Tzankov, Alexandar ;

Lundberg, Pontus ;

Muntion, Sandra ;

Tzeng, Yi-Shiuan ;

Lai, Dar-Ming ;

Schwaller, Juerg ;

Skoda, Radek C. ;

Mendez-Ferrer, Simon .

NATURE, 2014, 512 (7512) :78-+

← 1 2 3 4 5 6 7 8 9 10 →